Advances in CAR T cell immunotherapy for paediatric brain tumours
Brain tumours are the most common solid tumour in children and the leading cause of cancer related death in children. Current treatments include surgery, chemotherapy and radiotherapy. The need for aggressive treatment means many survivors are left with permanent severe disability, physical, intelle...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-11-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.873722/full |
| _version_ | 1798015859028918272 |
|---|---|
| author | Padmashree Rao Liam Furst Liam Furst Deborah Meyran Deborah Meyran Deborah Meyran Deborah Meyran Chelsea Mayoh Chelsea Mayoh Paul J. Neeson Paul J. Neeson Rachael Terry Rachael Terry Dong-Anh Khuong-Quang Dong-Anh Khuong-Quang Dong-Anh Khuong-Quang Theo Mantamadiotis Theo Mantamadiotis Paul G. Ekert Paul G. Ekert Paul G. Ekert Paul G. Ekert Paul G. Ekert Paul G. Ekert |
| author_facet | Padmashree Rao Liam Furst Liam Furst Deborah Meyran Deborah Meyran Deborah Meyran Deborah Meyran Chelsea Mayoh Chelsea Mayoh Paul J. Neeson Paul J. Neeson Rachael Terry Rachael Terry Dong-Anh Khuong-Quang Dong-Anh Khuong-Quang Dong-Anh Khuong-Quang Theo Mantamadiotis Theo Mantamadiotis Paul G. Ekert Paul G. Ekert Paul G. Ekert Paul G. Ekert Paul G. Ekert Paul G. Ekert |
| author_sort | Padmashree Rao |
| collection | DOAJ |
| description | Brain tumours are the most common solid tumour in children and the leading cause of cancer related death in children. Current treatments include surgery, chemotherapy and radiotherapy. The need for aggressive treatment means many survivors are left with permanent severe disability, physical, intellectual and social. Recent progress in immunotherapy, including genetically engineered T cells with chimeric antigen receptors (CARs) for treating cancer, may provide new avenues to improved outcomes for patients with paediatric brain cancer. In this review we discuss advances in CAR T cell immunotherapy, the major CAR T cell targets that are in clinical and pre-clinical development with a focus on paediatric brain tumours, the paediatric brain tumour microenvironment and strategies used to improve CAR T cell therapy for paediatric tumours. |
| first_indexed | 2024-04-11T15:40:27Z |
| format | Article |
| id | doaj.art-7c88f686e98245b38406baa48b3c0640 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-11T15:40:27Z |
| publishDate | 2022-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-7c88f686e98245b38406baa48b3c06402022-12-22T04:15:49ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-11-011210.3389/fonc.2022.873722873722Advances in CAR T cell immunotherapy for paediatric brain tumoursPadmashree Rao0Liam Furst1Liam Furst2Deborah Meyran3Deborah Meyran4Deborah Meyran5Deborah Meyran6Chelsea Mayoh7Chelsea Mayoh8Paul J. Neeson9Paul J. Neeson10Rachael Terry11Rachael Terry12Dong-Anh Khuong-Quang13Dong-Anh Khuong-Quang14Dong-Anh Khuong-Quang15Theo Mantamadiotis16Theo Mantamadiotis17Paul G. Ekert18Paul G. Ekert19Paul G. Ekert20Paul G. Ekert21Paul G. Ekert22Paul G. Ekert23Translational Tumour Biology, Children’s Cancer Institute, Randwick, NSW, AustraliaDepartment of Microbiology & Immunology, The University of Melbourne, Victoria, VIC, AustraliaMurdoch Children’s Research Institute, Royal Children’s Hospital, Melbourne, VIC, AustraliaCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, AustraliaSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, AustraliaUniversité de Paris, Inserm, U976 Human Immunology Pathophysiology Immunotherapy (HIPI) Unit, Institut de Recherche Saint-Louis, Paris, FranceChildren’s Cancer Centre, Royal Children’s Hospital, Parkville, VIC, AustraliaTranslational Tumour Biology, Children’s Cancer Institute, Randwick, NSW, AustraliaSchool of Women and Children’s Health, University of New South Wales, Randwick, NSW, AustraliaCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, AustraliaSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, AustraliaTranslational Tumour Biology, Children’s Cancer Institute, Randwick, NSW, AustraliaSchool of Women and Children’s Health, University of New South Wales, Randwick, NSW, AustraliaTranslational Tumour Biology, Children’s Cancer Institute, Randwick, NSW, AustraliaMurdoch Children’s Research Institute, Royal Children’s Hospital, Melbourne, VIC, AustraliaChildren’s Cancer Centre, Royal Children’s Hospital, Parkville, VIC, AustraliaDepartment of Microbiology & Immunology, The University of Melbourne, Victoria, VIC, AustraliaDepartment of Surgery Royal Melbourne Hospital (RMH), The University of Melbourne, Parkville, VIC, AustraliaTranslational Tumour Biology, Children’s Cancer Institute, Randwick, NSW, AustraliaMurdoch Children’s Research Institute, Royal Children’s Hospital, Melbourne, VIC, AustraliaCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, AustraliaSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, AustraliaSchool of Women and Children’s Health, University of New South Wales, Randwick, NSW, Australia0Department of Paediatrics, University of Melbourne, Parkville, VIC, AustraliaBrain tumours are the most common solid tumour in children and the leading cause of cancer related death in children. Current treatments include surgery, chemotherapy and radiotherapy. The need for aggressive treatment means many survivors are left with permanent severe disability, physical, intellectual and social. Recent progress in immunotherapy, including genetically engineered T cells with chimeric antigen receptors (CARs) for treating cancer, may provide new avenues to improved outcomes for patients with paediatric brain cancer. In this review we discuss advances in CAR T cell immunotherapy, the major CAR T cell targets that are in clinical and pre-clinical development with a focus on paediatric brain tumours, the paediatric brain tumour microenvironment and strategies used to improve CAR T cell therapy for paediatric tumours.https://www.frontiersin.org/articles/10.3389/fonc.2022.873722/fullCAR T cellimmunotherapypaediatric brain tumourtumour microenvironmentblood brain barrier |
| spellingShingle | Padmashree Rao Liam Furst Liam Furst Deborah Meyran Deborah Meyran Deborah Meyran Deborah Meyran Chelsea Mayoh Chelsea Mayoh Paul J. Neeson Paul J. Neeson Rachael Terry Rachael Terry Dong-Anh Khuong-Quang Dong-Anh Khuong-Quang Dong-Anh Khuong-Quang Theo Mantamadiotis Theo Mantamadiotis Paul G. Ekert Paul G. Ekert Paul G. Ekert Paul G. Ekert Paul G. Ekert Paul G. Ekert Advances in CAR T cell immunotherapy for paediatric brain tumours Frontiers in Oncology CAR T cell immunotherapy paediatric brain tumour tumour microenvironment blood brain barrier |
| title | Advances in CAR T cell immunotherapy for paediatric brain tumours |
| title_full | Advances in CAR T cell immunotherapy for paediatric brain tumours |
| title_fullStr | Advances in CAR T cell immunotherapy for paediatric brain tumours |
| title_full_unstemmed | Advances in CAR T cell immunotherapy for paediatric brain tumours |
| title_short | Advances in CAR T cell immunotherapy for paediatric brain tumours |
| title_sort | advances in car t cell immunotherapy for paediatric brain tumours |
| topic | CAR T cell immunotherapy paediatric brain tumour tumour microenvironment blood brain barrier |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.873722/full |
| work_keys_str_mv | AT padmashreerao advancesincartcellimmunotherapyforpaediatricbraintumours AT liamfurst advancesincartcellimmunotherapyforpaediatricbraintumours AT liamfurst advancesincartcellimmunotherapyforpaediatricbraintumours AT deborahmeyran advancesincartcellimmunotherapyforpaediatricbraintumours AT deborahmeyran advancesincartcellimmunotherapyforpaediatricbraintumours AT deborahmeyran advancesincartcellimmunotherapyforpaediatricbraintumours AT deborahmeyran advancesincartcellimmunotherapyforpaediatricbraintumours AT chelseamayoh advancesincartcellimmunotherapyforpaediatricbraintumours AT chelseamayoh advancesincartcellimmunotherapyforpaediatricbraintumours AT pauljneeson advancesincartcellimmunotherapyforpaediatricbraintumours AT pauljneeson advancesincartcellimmunotherapyforpaediatricbraintumours AT rachaelterry advancesincartcellimmunotherapyforpaediatricbraintumours AT rachaelterry advancesincartcellimmunotherapyforpaediatricbraintumours AT donganhkhuongquang advancesincartcellimmunotherapyforpaediatricbraintumours AT donganhkhuongquang advancesincartcellimmunotherapyforpaediatricbraintumours AT donganhkhuongquang advancesincartcellimmunotherapyforpaediatricbraintumours AT theomantamadiotis advancesincartcellimmunotherapyforpaediatricbraintumours AT theomantamadiotis advancesincartcellimmunotherapyforpaediatricbraintumours AT paulgekert advancesincartcellimmunotherapyforpaediatricbraintumours AT paulgekert advancesincartcellimmunotherapyforpaediatricbraintumours AT paulgekert advancesincartcellimmunotherapyforpaediatricbraintumours AT paulgekert advancesincartcellimmunotherapyforpaediatricbraintumours AT paulgekert advancesincartcellimmunotherapyforpaediatricbraintumours AT paulgekert advancesincartcellimmunotherapyforpaediatricbraintumours |